What is hairy cell leukaemia?
Hairy cell leukaemia (HCL) is a rare, slow-growing cancer of B lymphocytes, a type of white blood cell that normally helps to fight infection. Under the microscope, the leukaemia cells have fine, hair-like projections on their surface, which is how the disease got its name.
The abnormal cells build up in the bone marrow, the spleen and, to a lesser extent, the liver and blood. As they crowd out the normal marrow, the numbers of red blood cells, platelets and normal white cells fall. The spleen often becomes enlarged.
Although it is called a leukaemia, HCL behaves more like a low-grade (indolent) lymphoma. The World Health Organization (WHO) groups it with the splenic B-cell lymphomas and leukaemias.
HCL is one of the most treatable blood cancers. Most people respond very well to a short course of treatment, and many stay in remission for 10 years or more. People who reach a complete remission can usually expect a near-normal lifespan.
1. How common is it?
HCL makes up only about 2% of all leukaemias. It is diagnosed in roughly 1 in 300,000 people each year in Europe and North America.
| Feature | Details |
|---|---|
| Typical age | Usually 50-60; median age at diagnosis about 55. Very rare under 30 and almost never seen in children |
| Sex | About 4 times more common in men than in women |
| Ethnicity | More common in white people; less common in people of African and Asian origin |
| Main sites | Bone marrow, spleen, liver and blood; lymph nodes only occasionally |
| Course | Slow-growing; some people need no treatment for months or years after diagnosis |
2. Causes and risk factors
The cause of HCL is not fully known. It is not infectious, it cannot be passed to other people, and it does not usually run in families.
| Risk factor | What it means |
|---|---|
| Male sex and age over 50 | The clearest risk factors |
| Farming, pesticides and herbicides | Some studies show a small increase in risk; the link is not proven |
| Ionising radiation and organic solvents | Weak and inconsistent evidence |
| Family history | A few families with more than one case have been described, but this is very rare |
The BRAF V600E mutation
In 2011, researchers found that almost every case of classic HCL carries an acquired mutation in the BRAF gene called V600E. It is present in more than 95% of people with classic HCL.
BRAF V600E switches on a growth signal inside the cell (the MAPK/ERK pathway) all the time. It drives the leukaemia and gives the cells their typical features. This mutation develops during life in the leukaemia cells only, and it is not passed on to children.
Testing for BRAF V600E is now a standard part of diagnosis. It also opens the way to targeted drugs that block BRAF, such as vemurafenib.
A small group of people with HCL-like disease have no BRAF mutation. Some of them have tumours that use a particular antibody gene (IGHV4-34) or carry mutations in MAP2K1 (MEK1). These cases tend to behave and respond to treatment more like the variant form described below. Other genes, such as CDKN1B and KLF2, are also mutated in a minority of cases.
3. How does it look?
Most people with HCL look well at first, apart from looking pale or tired. The diagnosis is usually made from blood tests, the appearance of the cells under the microscope and special laboratory tests.
3.1 On the body
- Pale skin and tiredness, caused by anaemia.
- Bruising and small red or purple spots (petechiae) on the skin, caused by low platelets.
- A swollen abdomen or a feeling of fullness under the left ribs, from an enlarged spleen. In some people, the spleen reaches down into the lower abdomen.
- An enlarged liver in some people.
- Swollen lymph nodes are uncommon. When present, they are usually inside the abdomen and seen on scans.
3.2 In blood tests
| Test | Typical finding |
|---|---|
| Full blood count | Low levels of at least one, and often all three, blood cell types (pancytopenia) |
| Monocytes | Very low or absent; this is a typical clue to HCL |
| Neutrophils | Often low, which raises the risk of infection |
| Blood film | Small numbers of “hairy” cells may be seen; often there are very few |
3.3 Under the microscope
Hairy cells are medium-sized lymphocytes with plenty of pale blue cytoplasm and an oval or bean-shaped nucleus. Thin, hair-like projections stick out from the cell surface. In the bone marrow biopsy, the cells are spaced apart by clear cytoplasm, giving a “fried egg” appearance.
The bone marrow is often scarred with fibres (reticulin fibrosis). As a result, the doctor may be unable to draw out liquid marrow, which is called a “dry tap”. The biopsy core is then especially important.
| Test | Typical result in classic HCL |
|---|---|
| Flow cytometry | B-cell markers CD19, CD20 (bright) and CD22, together with CD11c, CD25, CD103 and CD123. CD5, CD10 and CD23 are usually negative |
| Immunohistochemistry on the biopsy | Annexin A1 (the most specific marker), TRAP, CD20, cyclin D1 (weak) and the BRAF V600E protein (VE1 stain) |
| Molecular test | BRAF V600E mutation found in more than 95% |
The combination of CD11c, CD25, CD103 and CD123 is very typical of classic HCL. Together with annexin A1 and BRAF V600E, it separates HCL from other B-cell lymphomas that involve the spleen.
3.4 HCL variant: now a separate disease
A rarer condition was long known as hairy cell leukaemia variant (HCL-v). It makes up about 1 in 10 HCL-like cases. Despite its name, it is biologically different from classic HCL.
| Feature | Classic HCL | HCL variant / SBLPN |
|---|---|---|
| Age | Median about 55 | Usually older, median about 70 |
| White cell count | Usually low | Usually high |
| Monocytes | Low | Normal |
| Cell appearance | Hairy cell with small or no nucleolus | Hairy features plus a prominent nucleolus |
| CD25, annexin A1, TRAP | Positive | Negative or weak |
| BRAF V600E | Present in more than 95% | Absent; MAP2K1 mutations in about 4 in 10 |
| Response to cladribine alone | Excellent | Poor; works better with rituximab |
The WHO 5th edition classification (2022) no longer uses the term HCL variant. Most of these cases are now classed as splenic B-cell lymphoma/leukaemia with prominent nucleoli (SBLPN). This new group also includes some cases previously called B-cell prolymphocytic leukaemia or splenic marginal zone lymphoma.
The separate International Consensus Classification (ICC, 2022) keeps the name HCL variant as a provisional entity. Doctors therefore may use either name. Both systems agree that it is a different disease from classic HCL and needs different treatment.
4. Symptoms
HCL usually develops slowly, and about 1 in 4 people have no symptoms when a routine blood test first shows a problem. When symptoms occur, they are caused by low blood counts or an enlarged spleen.
| Symptom | Cause |
|---|---|
| Tiredness, weakness, breathlessness | Anaemia (low red cells) |
| Repeated or unusual infections | Low neutrophils and monocytes; infections may be bacterial, fungal or caused by unusual organisms such as atypical mycobacteria |
| Easy bruising, nosebleeds, bleeding gums | Low platelets |
| Discomfort or a dragging feeling under the left ribs | Enlarged spleen |
| Feeling full after small meals | The enlarged spleen pressing on the stomach |
| Fever, night sweats or weight loss | Less common; may be caused by infection or by the leukaemia itself |
Less often, HCL causes skin rashes, joint pain or inflammation of the blood vessels (vasculitis). A very large spleen can rarely rupture after an injury, which causes sudden severe pain in the left upper abdomen.
When to see a doctor
See a doctor if you have ongoing tiredness, frequent infections, unexplained bruising or bleeding, or a feeling of fullness or pain under the left ribs. A fever of 38 degrees C or higher needs urgent medical attention if you have HCL or are being treated for it.
5. Diagnosis
HCL is diagnosed with blood tests, a bone marrow biopsy and laboratory tests on the cells.
5.1 Tests
| Test | Purpose |
|---|---|
| Full blood count and blood film | Shows low blood counts and may show hairy cells |
| Flow cytometry of blood or marrow | Identifies the typical marker pattern of HCL |
| Bone marrow aspirate and biopsy | Confirms the diagnosis and shows how much of the marrow is involved |
| BRAF V600E testing | Recommended for everyone at diagnosis; supports the diagnosis and guides later treatment |
| Blood chemistry | Kidney and liver function, LDH and other routine tests |
| Virus tests | Hepatitis B and C and HIV, before treatment |
| Ultrasound or CT scan | Measures the spleen and liver and looks for enlarged lymph nodes |
5.2 Conditions that can look similar
| Condition | How it differs |
|---|---|
| Splenic marginal zone lymphoma | Usually CD25-negative or weak, CD103-negative, annexin A1-negative, no BRAF V600E |
| SBLPN (HCL variant) | High white count, prominent nucleoli, CD25- and annexin A1-negative, no BRAF V600E |
| Chronic lymphocytic leukaemia | CD5- and CD23-positive, high lymphocyte count |
| Aplastic anaemia or myelodysplasia | Can also cause low counts and an empty-looking marrow; flow cytometry and marrow staining tell them apart |
6. Staging and when to treat
HCL has no formal staging system. Instead, doctors look at the blood counts, the size of the spleen and any symptoms.
Not everyone needs treatment straight away. People with no symptoms and reasonably good blood counts can be watched with regular blood tests (watch and wait).
According to the international consensus guidelines, treatment is usually started when one or more of the following are present:
- Haemoglobin below 11 g/dL
- Platelets below 100 x 10^9/L
- Neutrophils below 1 x 10^9/L
- An enlarged spleen that causes symptoms
- Repeated infections or other symptoms caused by HCL
Before treatment starts, any active infection should be treated. This is important because the first-line drugs lower the blood counts further for a few weeks.
7. Treatment
HCL guidelines include the ESMO Clinical Practice Guidelines, the British Society for Haematology guideline and international consensus guidelines. The consensus guidelines were first published in 2017 and updated in 2026 by an expert panel convened by the Hairy Cell Leukemia Foundation. They all agree that purine analogues are the backbone of first-line treatment.
7.1 First-line treatment
| Treatment | How it is given | Results | Main side effects |
|---|---|---|---|
| Cladribine | Injection under the skin or drip for 5 days (or a 7-day continuous drip), usually just one course | Complete remission in about 80-90%; median remission lasts many years | Very low neutrophils for 2-4 weeks, fever, infections, rash, long-lasting fall in lymphocytes |
| Pentostatin | Drip every 2 weeks, usually for 3-6 months | Similar results to cladribine | Low blood counts, nausea, tiredness, infections |
| Cladribine + rituximab | Cladribine as above, with 8 weekly drips of rituximab starting at the same time | Deeper remissions with no detectable leukaemia in almost all patients | As for cladribine, plus temporary low platelets and rituximab infusion reactions |
Purine analogues (cladribine and pentostatin) are chemotherapy drugs that are especially toxic to lymphocytes. In a UK study of 233 people followed for a median of 16 years, 80% reached complete remission after first-line treatment. The median time without relapse was 16 years.
Adding rituximab, an antibody against the CD20 marker on B cells, makes remissions deeper. In a randomised US trial, 97% of people given cladribine and rituximab together had a complete remission with no detectable leukaemia (minimal residual disease) at 6 months. This compared with 24% given cladribine alone. Most remained free of detectable disease after 8 years.
The 2026 consensus update recommends cladribine plus rituximab as a first-line option for fit patients. Cladribine or pentostatin alone also remain standard choices. For people who cannot have chemotherapy, for example because of a severe infection, a BRAF inhibitor with or without rituximab may be used instead.
7.2 Response to treatment
Response is usually checked with blood tests and a bone marrow biopsy several months after cladribine.
| Response | Meaning (simplified) |
|---|---|
| Complete remission | Normal blood counts, normal-sized spleen and no hairy cells seen in blood or marrow |
| Complete remission without MRD | As above, and no leukaemia found even with very sensitive tests |
| Partial remission | Blood counts normal or much better, with at least a 50% fall in leukaemia cells in the marrow and in spleen size |
7.3 Relapsed or refractory HCL
HCL can come back, often many years later. The choice of next treatment depends on how long the previous remission lasted.
| Situation | Usual options |
|---|---|
| Relapse after a long remission (for example more than 2-5 years) | Repeat a purine analogue, ideally with rituximab |
| Early relapse or no response to a purine analogue | Vemurafenib with rituximab; dabrafenib with trametinib; a different purine analogue with rituximab |
| Further relapses | BRAF inhibitors, BTK inhibitors such as ibrutinib, clinical trials |
Vemurafenib is a tablet that blocks the mutated BRAF protein. In two phase 2 trials in relapsed HCL, 96-100% of patients responded and 35-42% had a complete remission. However, without other treatment, relapse after stopping was common.
Given with rituximab for a short period of 8 weeks (vemurafenib) and 18 weeks (rituximab), complete remission was seen in 87% of patients. In 65% of those complete responders, no leukaemia could be detected. Vemurafenib does not lower the blood counts, so it is useful during infections.
Its side effects include rash, sensitivity to sunlight, joint pain, fever and small skin growths, including squamous cell skin cancers, which are easily removed. The skin should be checked regularly. Vemurafenib is not formally licensed for HCL in the EU or US and is used off-label, following the guidelines.
Dabrafenib plus trametinib combines a BRAF inhibitor with a MEK inhibitor. In a phase 2 trial in relapsed BRAF V600E-positive HCL, 89% responded and 66% had a complete response, with 94% free of progression at 2 years. Fever, chills and high blood sugar were the most common side effects.
Ibrutinib, a BTK inhibitor, works in about half of people with relapsed classic HCL or the variant form. It is taken continuously.
Moxetumomab pasudotox (Lumoxiti) was an anti-CD22 antibody linked to a bacterial toxin. It was approved in the US in 2018 for HCL that had come back after at least two previous treatments, with durable complete remissions in about a third of patients. Its use was limited by capillary leak syndrome and haemolytic uraemic syndrome. The manufacturer withdrew it from the EU in 2021 and from the US market in 2023 for commercial reasons, so it is no longer available.
Splenectomy (removal of the spleen) is now rarely needed. It may still help a person with a very large, painful spleen that does not respond to drugs, or during pregnancy.
7.4 Treatment of the variant form (SBLPN)
Cladribine alone works poorly in the variant form. The usual first-line treatment is cladribine plus rituximab, which gives much better responses.
BRAF inhibitors do not work because the BRAF V600E mutation is absent. Options at relapse include bendamustine with rituximab, ibrutinib and clinical trials. The variant form usually needs more treatment over time, and the outlook is less favourable than for classic HCL.
7.5 Supportive care
| Area | What is done |
|---|---|
| Infection prevention | Many centres give aciclovir (against shingles and herpes) and co-trimoxazole (against pneumocystis pneumonia) after purine analogues, until the lymphocyte count recovers |
| Fever during treatment | Needs urgent assessment and antibiotics in hospital |
| Blood transfusions | After purine analogues, only irradiated blood products should be used, usually for life, to prevent a rare transfusion reaction |
| Hepatitis B | People with past infection take antiviral tablets during rituximab treatment |
| Vaccines | Inactivated vaccines such as flu, pneumococcal and COVID-19 are recommended, ideally before treatment. Live vaccines should be avoided |
| Skin checks | Regular skin examinations during BRAF inhibitor treatment |
8. Prognosis
The outlook for classic HCL is excellent. Before purine analogues were introduced in the 1980s, median survival was only about 4 years. Today, most people live for many years, and those who reach complete remission can expect a normal lifespan.
- About 80-90% of people reach complete remission after a single course of cladribine or pentostatin.
- About half relapse, but often only after 10-15 years. People still in remission at 5 years have only about a 25% risk of relapse by 15 years.
- A second or third course of treatment often works as well as the first.
- Adding rituximab to cladribine makes remissions deeper, and early results suggest they may last even longer.
- The variant form (SBLPN), BRAF-negative disease using IGHV4-34 and disease that does not respond to first-line treatment have a less favourable outlook.
People with HCL have a slightly higher risk of developing a second cancer, such as skin cancer or another lymphoma. Age-appropriate cancer screening and sun protection are therefore advised.
9. Follow-up and living with HCL
9.1 Follow-up
After treatment, people are usually seen every 3-6 months for the first few years and then less often. Each visit includes a blood count and a check of the spleen.
A rise in hairy cells in the blood or a fall in blood counts may be the first sign of relapse. A new bone marrow biopsy is done only if treatment is being considered.
9.2 Everyday life
- Most people return to normal activities, including work and exercise, once their blood counts recover.
- Report fever, chills, persistent cough or other signs of infection promptly, especially in the months after treatment.
- Tell every doctor that you have had a purine analogue, because you will need irradiated blood if you ever need a transfusion.
- Protect your skin from the sun, and report new or changing skin spots, especially if you take a BRAF inhibitor.
- Women should avoid becoming pregnant, and men should avoid fathering a child, during treatment and for a period afterwards; ask your team how long this should be.
- Patient groups such as the Hairy Cell Leukemia Foundation offer information, support and patient meetings.
Resources
- Tiacci, E. et al. (2011) ‘BRAF mutations in hairy-cell leukemia’, New England Journal of Medicine, 364(24), pp. 2305-2315.
- Waterfall, J.J. et al. (2014) ‘High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias’, Nature Genetics, 46(1), pp. 8-10.
- Alaggio, R. et al. (2022) ‘The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms’, Leukemia, 36(7), pp. 1720-1748.
- Robak, T. et al. (2015) ‘Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up’, Annals of Oncology, 26(Suppl 5), pp. v100-v107.
- Grever, M.R. et al. (2017) ‘Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia’, Blood, 129(5), pp. 553-560.
- Zent, C.S. et al. (2026) ‘Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant’, Blood, 148(1), pp. 31-42.
- Parry-Jones, N. et al. (2020) ‘Guideline for diagnosis and management of hairy cell leukaemia (HCL) and hairy cell variant (HCL-V)’, British Journal of Haematology, 191(5), pp. 730-737.
- Else, M. et al. (2009) ‘Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis’, British Journal of Haematology, 145(6), pp. 733-740.
- Chihara, D. et al. (2020) ‘Randomized phase II study of first-line cladribine with concurrent or delayed rituximab in patients with hairy cell leukemia’, Journal of Clinical Oncology, 38(14), pp. 1527-1538.
- Tiacci, E. et al. (2015) ‘Targeting mutant BRAF in relapsed or refractory hairy-cell leukemia’, New England Journal of Medicine, 373(18), pp. 1733-1747.
- Tiacci, E. et al. (2021) ‘Vemurafenib plus rituximab in refractory or relapsed hairy-cell leukemia’, New England Journal of Medicine, 384(19), pp. 1810-1823.
- Kreitman, R.J. et al. (2023) ‘Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia’, Blood, 141(9), pp. 996-1006.
- Kreitman, R.J. et al. (2021) ‘Moxetumomab pasudotox in heavily pre-treated patients with relapsed/refractory hairy cell leukemia (HCL): long-term follow-up from the pivotal trial’, Journal of Hematology & Oncology, 14(1), p. 35.
- Rogers, K.A. et al. (2021) ‘Phase 2 study of ibrutinib in classic and variant hairy cell leukemia’, Blood, 137(25), pp. 3473-3483.
- ESMO (2026) ESMO Clinical Practice Guideline: Hairy Cell Leukaemia. Available at: https://www.esmo.org/guidelines/esmo-clinical-practice-guideline-hairy-cell-leukaemia (Accessed: October 2026).
- National Cancer Institute (2026) Hairy Cell Leukemia Treatment (PDQ) – Patient Version. Available at: https://www.cancer.gov/types/leukemia/patient/hairy-cell-treatment-pdq (Accessed: October 2026).
Prepared by the editorial team, October 2026.